What is the current treatment of patients with essential thrombocytopenia and other myeloproliferations accompanied with thrombocytopenia, and what can be the predictive sign of the risk of thrombosis in such patients - a report from the registry of patients treated by Thromboreductine
2008
Abstract
The registry of patients treated with Thromboreductine (anagrelid) in the contributing centres in the Czech Republic has been updated with data on the patients receiving this medication since 2004. The original purpose of the registry was to record responses to Thromboreductine therapy and adverse drug reactions in patients with essential thrombocytopenia.
However, data on additional Ph negative myeloproliferations, as well as data on cytoreductive therapies other than exclusively that using Thromboreductine has also been recorded in the course of its compilations, including data on combined regimes.